Mar 24,2022

Abbott Diabetes Care Diabetes Care'S FREESTYLE® LIBRE IS FIRST AND ONLY CGM SYSTEM TO GAIN EXPANDED REIMBURSEMENT IN JAPAN TO INCLUDE ALL PEOPLE WITH DIABETES WHO USE INSULIN

Abbott Diabetes Care Diabetes Care (NYSE: ABT) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the expansion of reimbursement coverage for its FreeStyle® Libre system to include all people with diabetes who use insulin at least once a day.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 26,2022

Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study

This study examined the durability of continuous glucose monitoring (CGM) coupled with a family behavioral intervention (FBI) to improve glycemia.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 30,2022

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott Diabetes Care Diabetes Care, Dexcom

Analysts have suggested that companies like Abbott Diabetes Care Diabetes Care (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in continuous glucose monitors (CGMs) among type 2 diabetes non-intensive insulin therapy (T2 NIIT) patients.

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 01,2022

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. (NASDAQ:DXCM) announced today the new DexCom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May.

PRODUCT

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 04,2022

ASCENSIA DIABETES CARE LAUNCHES THE 6 MONTH EVERSENSE® E3 CONTINUOUS GLUCOSE MONITORING SYSTEM IN THE U.S. WITH THE NEW EVERSENSE PASS SAVINGS PROGRAM

Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System for patients in the U.S., alongside the new Eversense PASS savings program.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 07,2022

Senseonics announces first Eversense E3 CGM implant in U.S.

Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days).

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 11,2022

Diabetes Specialists Value CGM Despite Challenges in Prescribing and Data Review Process

Diabetes clinicians are key facilitators of continuous glucose monitoring (CGM) provision, but data on provider behavior related to CGM use and CGM generated data are limited.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 13,2022

Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit

Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

In Vitro Continuous 3 Months Operation of Direct Electron Transfer Type Open Circuit Potential Based Glucose Sensor: Heralding the Next CGM Sensor

While continuous glucose monitoring (CGM) systems allow precise and real-time blood glucose control, current electrochemicalbased CGM technologies inherently harbor enzyme instability issues.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project

This consensus aims to evaluate the degree of agreement among Spanish experts on the role of isCGM in the evaluation of glycemic variability, reduction of glycosylated hemoglobin (HbA1c) levels, and selection and adjustment of insulin therapy.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM